CXCL13 and B-cell chronic lymphocytic leukemia: The authors also found that treatment with ibrutinib disrupts the interaction between tumor-associated macrophages (TAM) and tumor cells in the bone marrow, inhibits the secretion of CXCL13, and decreases the chemoattraction of CLL cells [43].